Skye Bioscience, Inc. Net Income Loss

• Skye Bioscience, Inc. showed a decrease of -110.5% in Net Income Loss from 2024 to 2025.
• This data is from Skye Bioscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2012 to 2025), Skye Bioscience, Inc.'s Net Income Loss has declined by 1,240,393.1%.
• Historical annual values: Fiscal year 2025: -$55.92 million | Fiscal year 2024: -$26.57 million | Fiscal year 2023: -$37.64 million | Fiscal year 2022: -$19.48 million | Fiscal year 2021: -$8.52 million | Fiscal year 2020: -$6.56 million | Fiscal year 2019: $1.05 million | Fiscal year 2018: -$19.19 million | Fiscal year 2017: -$3.09 million | Fiscal year 2016: -$3.18 million | Fiscal year 2015: -$4.84 million | Fiscal year 2014: -$2.73 million | Fiscal year 2013: -$120.4 thousand | Fiscal year 2013: -$3.8 thousand | Fiscal year 2012: $4.5 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026